Anti-EGFRvIII [L8A4] Antibody

This mouse IgG1 monoclonal antibody was generated against Pep 3, a 14-amino acid peptide corresponding to the predicted amino acid sequence at the fusion junction (LEEKKGNYVVTDHC), and is specific for human epidermal growth factor receptor variant III (EGFRvIII).

Highlights:

  • Reacts with human EGFRvIII
  • Suitable for Western Blot, Immunohistochemistry, ELISA and Flow Cytometry applications

The epidermal growth factor receptor is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor receptor (EGFR) exists in a deletion-mutant form, EGFRvIII, which has been identified by genetic and immunological means in a subset of gliomas and non-small cell lung carcinomas.

From the laboratory of Darell D. Bigner, MD, PhD, Duke University.

Catalog Number Product Size AVAILABILITY Price Qty
EDK002
Anti-EGFRvIII [L8A4] Antibody, 100ug
100ug In stock
Price: $299.00
Specifications
Product Type: Antibody
Antigen: EGFRvIII
Molecular Weight: 145 kDa
Isotype: IgG1
Clonality: Monoclonal
Clone Name: L8A4
Reactivity: Human
Immunogen: Pep 3, a 14-amino acid peptide corresponding to the predicted amino acid sequence at the fusion junction (LEEKKGNYVVTDHC), was synthesized, purified, and coupled to keyhole limpet hemocyanin
Species Immunized: Mouse
Purification Method: Protein G
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: WB (20 ug/mL), Immunohistochemistry, ELISA, flow cytometry
Storage: -20C
Shipped: Cold Packs
Provider
From the laboratory of Darell D. Bigner, MD, PhD, Duke University.

References
  1. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995 Jul 15;55(14):3140-8

If you publish research with this product, please let us know so we can cite your paper.

 
Loading...
Loading...